Novynette pills №21

Indications and usage

Oral contraception (first choice drug). Functional disorders of the menstrual cycle, dysmenorrhea, premenstrual syndrome.

Contraindications

 
Hypersensitivity to the components of the drug, pregnancy, breast-feeding, severe liver disease, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), cholelithiasis, cholecystitis, chronic colitis; the presence or indication in the history of severe cardiovascular and cerebrovascular changes, thromboembolism and predisposition to them, liver tumors, malignant tumors, especially breast cancer or endometrium; hyperlipoproteinemia, severe hypertension, severe diabetes mellitus with vascular complications, sickle cell anemia, chronic hemolytic anemia, vaginal bleeding of unknown etiology, migraine, otosclerosis; history of idiopathic jaundice in pregnant women, severe pruritus or herpes in pregnant women.

Adverse reactions

Side effects are very rare. Due to the minimal estrogen component, the risk of acyclic bleeding increases. Novynette requires a very careful implementation of the rules of its reception (regular, at the same time of day, without skipping pills).

From the nervous system and sensory organs: headache, migraine, mood changes, depressive states, Sydengam's chorea.
Since the cardiovascular system and blood (hematopoiesis, hemostasis): very rarely - increased risk of arterial and venous thromboembolic diseases (for example, myocardial infarction, stroke, deep vein thrombosis of the lower extremities, pulmonary thromboembolism); hypertension.
On the part of the digestive tract: nausea, vomiting, gallstone disease, cholestatic jaundice.
From the genitourinary system: intermenstrual bleeding, amenorrhea, change in vaginal mucus, candidiasis.
From the skin: nodular erythema, rash, chloasma.
Allergic reactions: very rarely - exacerbation of reactive systemic lupus erythematosus.
Other: tension, pain, increase and release of milk from the mammary glands; increased corneal sensitivity while wearing contact lenses; fluid retention, change in body weight, decrease in carbohydrate tolerance.

Pregnancy and breastfeeding

Acceptance of oral contraceptives, which preceded pregnancy, does not increase the risk of various defects of the fetus. Unintentional use of hormonal contraceptives in the early stages of pregnancy does not have a teratogenic or mutagenic effect, does not affect the sex of the fetus. At the same time, it should be remembered that, according to the FDA classification, estrogens and progestins according to the risk level during pregnancy are classified as X.
The possible risk associated with taking hormonal contraceptives in this case greatly exceeds the benefit; when pregnancy is established and if it is suspected, steroid hormones should be abolished.

Drug interactions

Novynette should not be used in combination: 
- with inducers of hepatic microsomal oxidation, such as rifampicin, derivatives of phenobarbital, anticonvulsa detection agents (phenytoin, carbamazepine), dihydroergocamine, some tranquilizers, phenylbutazone, Ketoconazole, as well as with broad-spectrum antibiotics (tetracycline, I, and I, and I, and I, and I, and I, with a combination of antibiotics and ketoconazole, as well as with broad-spectrum antibiotics (tetracycline, I, and I), and with broad-spectrum antibiotics (I-tetracycline, I, and I, and I, I, and I, and I, with the use of broad-spectrum antibiotics, and Tetracycline, I, and I, and I, and I, and I, with the use of broad-spectrum antibiotics; for a high risk of reducing the contraceptive effect of Novynette.

Novynette should be used with caution in combination:
  - with anticoagulants derived from coumarin or indandion (it may be necessary to control the prothrombin time and change the dose of the anticoagulant);
- with tricyclic antidepressants, maprotiline; beta-blockers (the bioavailability and, therefore, the toxicity of these drugs may increase);
- with oral antidiabetic drugs, insulin (it may be necessary to change their dose);
- with Bromocriptine (reduced efficacy);
- with hepatotoxic drugs, especially with dantrolene (the risk of increased hepatotoxicity, especially in women over 35 years).

Before you start using the drug, it is necessary to conduct a general medical and gynecological examination (first of all, blood pressure measurement, determination of blood sugar levels, liver function tests,breast examination, cytological analysis of cervical smear) to eliminate the risk of illness and pregnancy.
For women with a family history of thromboembolic diseases at a young age or a bleeding disorder, Novynette is not recommended.
Special care is required in the presence of diabetes, heart disease, non-ischemic etiology, hypertension, renal dysfunction, thrombophlebitis, otosclerosis, multiple sclerosis, epilepsy, minor chorea, intermittent porphyria, latent tetany, bronchial asthma.
While taking the drug requires medical supervision no less than every 6 months.
After viral hepatitis, oral contraceptive use is allowed no earlier than 6 months, provided that the hepatic functions are normalized.
On the background of a long (more than 8 years) continuous use of sex hormones, benign, very rarely - malignant liver tumors were very rarely observed. When a sharp pain in the upper abdomen, hepatomegaly and signs of intra-abdominal hemorrhage appear, a liver tumor may be suspected. In this case, the drug should be discontinued to determine the cause. When violations of the liver functions during the administration of the drug, it is necessary to monitor the condition of the therapist every 2-3 months.
In the absence of menstrual bleeding, the continuation of admission is allowed only after the exclusion of pregnancy.
With the appearance of intermenstrual bleeding, especially in the first 2-3 months, you should continue taking Novynette, since in most cases these bleeding stop spontaneously. If intermenstrual bleeding does not disappear or recur, a medical examination is required to exclude pathology of internal organs.
In the event of vomiting or diarrhea, the pill should be continued, but it is recommended to use an additional, mechanical method of contraception.
In women taking oral contraceptive preparations containing estrogen, the likelihood of developing thromboembolism of different localization may increase. This risk increases with age, mainly in smokers. In this regard, women older than 30 years, taking oral contraceptives, it is recommended to completely stop smoking.
If a woman is planning a pregnancy, the drug should be stopped no less than three months before the intended time of conception.

Immediately stop taking Novinet:
  - in the case of a first-time or aggravated migraine-like, unusually severe headache, with acute deterioration of vision, with suspected thrombosis or cerebral infarction;
- With a sharp increase in blood pressure, with the development of jaundice or hepatitis without jaundice, with the occurrence of generalized itching, with the occurrence or increase of epileptic seizures;
- at the planned operation (6 weeks before the operation), with prolonged immobilization (for example, after injuries)

Storage conditions

At a temperature of 15 ° - 30 ° C, out of the reach of children.